Stocktoria
PolyPid Ltd. PYPD
PolyPid Ltd. (PYPD) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PYPD | PolyPid Ltd. | 2/9 | — | — | — |
| MDLN | Medline Inc. | 6/9 | 2.84 | 44.1 | +11.5% |
| SYK | STRYKER CORP | 4/9 | 3.96 | 39.3 | +11.2% |
| MMM | 3M CO | 5/9 | 5.46 | 26.3 | +1.5% |
| BDX | BECTON DICKINSON & CO | 6/9 | 2.29 | 25.6 | +8.2% |
| BSX | BOSTON SCIENTIFIC CORP | 4/9 | 2.81 | — | +19.9% |
| BAX | BAXTER INTERNATIONAL INC | 5/9 | 3.86 | — | +5.7% |
About PolyPid Ltd.
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
FAQ
Is PYPD financially healthy?
PolyPid Ltd.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does PYPD pay a dividend?
No, PolyPid Ltd. does not currently pay a dividend.
How profitable is PYPD?
In FY2025, PolyPid Ltd. had a return on equity of -311.4%.
Is PYPD overvalued or undervalued?
PolyPid Ltd. trades at about 2.3× trailing earnings — above its 10-year norm (10-year range 0.4×–62.9×, median 2.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for PYPD?
The average Wall-Street price target for PolyPid Ltd. is $12.25, about 153.1% above the recent price, from 4 analysts.
Is PYPD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PolyPid Ltd.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.